This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (13)  • Contact me when this article is cited  Related Content  • Related letter  • Similar articles in JAMA  Topic Collections  • Medical Practice  • Conflict of Interest  • Tobacco  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Bhavna Shamasunder, MES; Lisa Bero, PhD

JAMA. 2002;288:738-744.

Corporate diversification allows for well-hidden financial ties between pharmaceutical and tobacco companies, which can cause a conflict of interest in the development and marketing of pharmaceutical products. In our investigation of tobacco company documents released and posted on the Internet as a result of the Master Settlement Agreement, we have found that these financial ties have fostered both competition and collaboration between the tobacco and pharmaceutical industries. We present 3 case studies. One shows how tobacco companies pressured pharmaceutical companies to scale back their smoking cessation educational materials that accompanied Nicorette. The second shows how they restricted to whom the pharmaceutical company could market its transdermal nicotine patch. In the third case, we show how subsidiary tobacco and pharmaceutical companies of a parent company collaborated in the production of a nicotine-release gum. Thus, because tobacco cessation product marketing has been altered as a result of these financial conflicts, disclosure would serve the interest of public health.

Author Affiliations: Institute for Health Policy Studies (Ms Shamasunder), Department of Clinical Pharmacy, Institute for Health Policy Studies (Dr Bero), University of California, San Francisco.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTER

Relationships Between Pharmaceutical and Tobacco Companies
Terry Barnett, Hiroshi Kawane, Lisa Bero, and Bhavna Shamasunder
JAMA. 2002;288(23):2973.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

How tobacco protects you against the flu
Schneider and Ling
Tobacco Control 2008;17:215-216.
ABSTRACT | FULL TEXT  

Tobacco control implications of the first European product liability suit
Hiilamo
Tobacco Control 2005;14:22-30.
ABSTRACT | FULL TEXT  

A nicotine delivery device without the nicotine? Tobacco industry development of low nicotine cigarettes
Dunsby and Bero
Tobacco Control 2004;13:362-369.
ABSTRACT | FULL TEXT  

A glossary for evidence based public health
Rychetnik et al.
J. Epidemiol. Community Health 2004;58:538-545.
ABSTRACT | FULL TEXT  

Promotion of smoking cessation in developing countries: a framework for urgent public health interventions
Abdullah and Husten
Thorax 2004;59:623-630.
ABSTRACT | FULL TEXT  

Relationships Between Pharmaceutical and Tobacco Companies
Barnett et al.
JAMA 2002;288:2973-2973.
FULL TEXT  

Tobacco giant undermined Nicorette campaign
Moynihan
BMJ 2002;325:353-353.
FULL TEXT